Published in Oncogene on August 26, 1999
The sensitivity of activated Cys Ret mutants to glial cell line-derived neurotrophic factor is mandatory to rescue neuroectodermic cells from apoptosis. Mol Cell Biol (2001) 0.83
Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers. Curr Genomics (2011) 0.82
A PCR-mutagenesis strategy for rapid detection of mutations in codon 634 of the ret proto-oncogene related to MEN 2A. BMC Med Genet (2002) 0.75
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. Oncology (2016) 0.75
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet (2003) 18.67
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer (2008) 3.87
A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature (1994) 3.87
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (2000) 3.50
Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature (1994) 3.46
Malignant activation of a K-ras oncogene in lung carcinoma but not in normal tissue of the same patient. Science (1984) 2.97
PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol (2008) 2.75
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature (1987) 2.60
The FHIT gene 3p14.2 is abnormal in lung cancer. Cell (1996) 2.36
Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci U S A (1997) 2.36
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol (1999) 2.11
Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Mol Cell Biol (1993) 2.08
Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res (1998) 1.96
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene (1989) 1.94
Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet (2005) 1.91
Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene (1994) 1.87
Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res (1996) 1.85
Mutations that impair swarming motility in Serratia marcescens 274 include but are not limited to those affecting chemotaxis or flagellar function. J Bacteriol (1992) 1.76
Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res (2001) 1.76
bcl-2 proto-oncogene expression in normal and neoplastic human myeloid cells. Blood (1992) 1.69
A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res (1996) 1.60
Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer (1991) 1.58
Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J Clin Invest (1993) 1.57
TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene (1992) 1.55
p53 activity and chemotherapy. Nat Med (1996) 1.53
Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest (1992) 1.52
Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas. Oncogene (1992) 1.51
Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res (1992) 1.50
Structural features and selective expression of three Ly-5+ cell-surface molecules. Immunogenetics (1981) 1.47
The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci U S A (1999) 1.47
CD34 expression is regulated reciprocally with adhesion molecules in vascular endothelial cells in vitro. Blood (1993) 1.44
The relationship of plasma glucose and electrocardiographic parameters in elderly women with different degrees of glucose tolerance. Aging (Milano) (2000) 1.41
Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res (1997) 1.39
Diagnosing mental disorders in primary care: the General Health Questionnaire (GHQ) and the Symptom Check List (SCL-90-R) as screening instruments. Soc Psychiatry Psychiatr Epidemiol (1999) 1.38
The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol Cell Biol (1995) 1.38
Cancer genetic counselling. Ann Oncol (2005) 1.38
Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res (1995) 1.33
Loss of function effect of RET mutations causing Hirschsprung disease. Nat Genet (1995) 1.33
A novel zinc finger gene is fused to EWS in small round cell tumor. Oncogene (2000) 1.33
Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol (2009) 1.33
Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Invest (2000) 1.30
Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene (2007) 1.28
Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest (2001) 1.26
Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer (2001) 1.26
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res (1994) 1.22
Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol (1994) 1.20
Characterization of ten novel and 13 recurring BRCA1 and BRCA2 germline mutations in Italian breast and/or ovarian carcinoma patients. Mutations in brief no. 178. Online. Hum Mutat (1998) 1.19
A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nat Genet (1993) 1.18
Absence of Fhit protein in primary lung tumors and cell lines with FHIT gene abnormalities. Cancer Res (1997) 1.18
Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J Pathol (1997) 1.18
Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene (2006) 1.17
Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. J Pathol (1998) 1.15
A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas. Genomics (1995) 1.14
p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol (2000) 1.14
The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins. Oncogene (1994) 1.14
Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer. Cancer Lett (2008) 1.11
Mapping of body weight loci on mouse chromosome X. Mamm Genome (1995) 1.10
The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol (1996) 1.09
PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol (2006) 1.08
Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells. J Biol Chem (2000) 1.08
Refined localization to contiguous regions on chromosome 10q of the two genes (H4 and RET) that form the oncogenic sequence PTC. Oncogene (1991) 1.07
RET activation by germline MEN2A and MEN2B mutations. Oncogene (1995) 1.07
4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem (1996) 1.07
The oncogene associated with human papillary thyroid carcinoma (PTC) is assigned to chromosome 10 q11-q12 in the same region as multiple endocrine neoplasia type 2A (MEN2A). Oncogene (1989) 1.07
Aberrant FHIT transcripts in Merkel cell carcinoma. Cancer Res (1996) 1.06
Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res (1995) 1.06
IL-4 prevents the blockade of dendritic cell differentiation induced by tumor cells. Cancer Res (2001) 1.05
Cytogenetic abnormalities and overexpression of receptors for growth factors in normal bronchial epithelium and tumor samples of lung cancer patients. Cancer Res (1991) 1.05
11q deletions in human colorectal carcinomas: cytogenetics and restriction fragment length polymorphism analysis. Genes Chromosomes Cancer (1993) 1.05
IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene (2010) 1.05
Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur J Cancer (1994) 1.05
RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res (1998) 1.05
Detection of microsatellite alterations in plasma DNA of non-small cell lung cancer patients: a prospect for early diagnosis. Clin Cancer Res (1999) 1.04
Identification of Shc docking site on Ret tyrosine kinase. Oncogene (1997) 1.04
Increased apoptosis, Huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects. Cell Death Differ (2006) 1.04
Chromosome mapping of murine susceptibility loci to liver carcinogenesis. Cancer Res (1993) 1.03
Genetic mapping of lung cancer modifier loci specifically affecting tumor initiation and progression. Cancer Res (1997) 1.03
Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. Oncogene (1997) 1.03
The expression of MDM2/CDK4 gene product in the differential diagnosis of well differentiated liposarcoma and large deep-seated lipoma. Br J Cancer (2000) 1.03
Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer (1997) 1.02
The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res (2002) 1.02